Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14777737 | 1.00 | ALDH1A1 (0.53) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL14788490 | 0.89 | ALDH1A1 (0.56) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL19324273 | 0.85 | ALDH1A1 (0.51) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL9115522 | 0.85 | ALDH1A1 (0.51) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL21560929 | 0.85 | ALDH1A1 (0.55) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL31153737 | 0.85 | ALDH1A1 (0.55) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL17563423 | 0.85 | ALDH1A1 (0.55) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL18732578 | 0.83 | ALDH1A1 (0.53) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL14777615 | 0.83 | SLC15A1 (0.49) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL4902613 | 0.83 | ALDH1A1 (0.56) | ALDH1A1TDP1KMT2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| EP-2576500-A2 | PROCESS FOR PRODUCING ALISKIREN | Chemo Iberica, S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| US-20130071899-A1 | Process for Producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2013-03-21 | — | — | US | disclosed |
| US-20130071899-A1 | Process for Producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2013-03-21 | — | — | US | disclosed |
| US-20130071899-A1 | Process for Producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2013-03-21 | — | — | US | disclosed |
| WO-2011151442-A2 | PROCESS FOR PRODUCING ALISKIREN | CHEMO IBERICA, S.A. (ES) | 2011-12-08 | — | — | WO | disclosed |
| EP-1082127-B1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYME | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1082127-A4 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER LAMBERT CO (US) | 2002-10-09 | — | — | EP | disclosed |
| CN-1308542-A | Succinamide inhibitors of interleukin-1 beta converting enzyme | WARNET LAMBERT CO (US) | 2001-08-15 | — | — | CN | disclosed |
| EP-1082127-A1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999056765-A1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071899-A1 | Process for Producing Aliskiren | REN, AGTR1, AGTR2 | ALDH1A1 1182/4885TDP1 4453/4885KMT2A 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.